Mrna Therapeutics Market to Reach USD 61.0 Billion by 2034 at 12.00% CAGR - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - The technology that turned mRNA into a household term during the COVID-19 pandemic is now moving well beyond vaccines. Advances in delivery platforms, including lipid nanoparticles and polymer-based carriers, are enabling developers to pursue applications in oncology, rare and genetic disease, and gene editing that were out of reach only a few years ago. According to a new report from Strategic Revenue Insights, the global mRNA therapeutics market was valued at USD 22.0 billion in 2025 and is projected to reach USD 61.0 billion by 2034, growing at a CAGR of 12.00% over the forecast period. The report was led by analyst Anirudh Singh, with findings drawn from primary interviews with pharmaceutical executives, biotechnology researchers, and healthcare providers, supplemented by secondary data across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa.

Key Takeaways

• The mRNA therapeutics market is valued at USD 22.0 billion in 2025 and is forecast to reach USD 61.0 billion by 2034, a CAGR of 12.00%.
• Prophylactic mRNA vaccines remain the largest product segment, while therapeutic cancer vaccines are the fastest-growing, driven by rising cancer prevalence and demand for targeted therapies.
• Lipid nanoparticle delivery technology continues to lead adoption, improving the stability, safety, and efficacy of mRNA-based therapies.
• North America leads the market on the strength of advanced healthcare infrastructure and R&D investment, while Asia Pacific is the fastest-growing region amid rising healthcare spending and a growing patient population.
• Moderna, BioNTech, and Pfizer are the leading companies, having built market share through COVID-19 vaccine rollouts and continued investment in mRNA research.

Full report access: https://www.strategicrevenueinsights.com/industry/mrna-therapeutics-market

From Pandemic Response to Precision Medicine

The market's momentum traces directly back to the success of mRNA-based COVID-19 vaccines, which demonstrated the platform's speed and adaptability at scale. Moderna and BioNTech, in particular, showed that mRNA technology could move from concept to authorized therapy faster than conventional vaccine development allows, and that early proof point continues to shape how the rest of the industry invests. Regulatory bodies responded with expedited approval pathways for mRNA-based COVID-19 vaccines, and that precedent is now informing how newer mRNA therapies move through review.

Growth is increasingly driven by the shift toward personalized medicine. mRNA's ability to be reprogrammed for a specific target makes it well suited to individualized treatment, and companies are directing R&D spending toward therapies tailored to a patient's genetic profile rather than one-size-fits-all treatments. This is reinforced by rising investment in biotechnology research, much of it backed by government initiatives and funding, and by growing awareness among healthcare professionals and patients of what mRNA-based treatment can offer.

Delivery technology is the other half of the story. Improvements in lipid nanoparticles and polymer-based carriers are what make it possible to extend mRNA beyond prophylactic vaccines into oncology, rare and genetic disease, and gene-editing delivery, and continued investment in these platforms is expected to keep unlocking new therapeutic areas through the forecast period.

Market Segmentation

By product type, prophylactic mRNA vaccines lead the market, a position built on the success of COVID-19 vaccines and continued investment in expanding vaccine portfolios beyond COVID-19. Therapeutic cancer vaccines are the fastest-growing product type, reflecting rising cancer prevalence and demand for targeted oncology treatment, while protein replacement therapies, cell therapy reprogramming, and gene editing delivery are emerging as growth areas for rare and genetic disease treatment.

By delivery technology, lipid nanoparticles lead due to their proven efficacy and safety in stabilizing and delivering mRNA molecules. Polymer-based carriers are gaining traction as a versatile, customizable alternative, while exosome-based delivery is an emerging approach that companies are exploring to further improve delivery and efficacy. Naked mRNA and electroporation remain in use for specific applications.

By application, infectious diseases and oncology lead the market, extending the pattern set by COVID-19 vaccines into cancer treatment through therapeutic cancer vaccines and targeted therapies. Rare and genetic diseases represent a significant application area as mRNA technology offers solutions for previously untreatable conditions, and cardiovascular and autoimmune disorders are emerging as additional application areas under active exploration.

By end use, hospitals and clinics are the dominant setting, reflecting their role as the primary point of care for patients receiving mRNA-based therapies. Vaccination centers are also significant end users, a role that grew substantially during the COVID-19 pandemic, while research institutes and contract manufacturing organizations play a central role in developing and supplying mRNA therapeutics to meet growing demand.

Regional Outlook

North America is the largest regional market, supported by advanced healthcare infrastructure and significant R&D investment. Asia Pacific is the fastest-growing region, driven by increasing healthcare investment and a growing patient population. The report also covers Latin America, Europe, and the Middle East & Africa as part of its regional scope, rounding out a global view of mRNA therapeutics demand.

Competitive Landscape

Moderna, BioNTech, and Pfizer are the market's leading companies, each having captured significant share through successful COVID-19 vaccine rollouts and ongoing mRNA research. Moderna continues to expand its market presence through strategic collaborations and a broad pipeline of mRNA-based therapies. BioNTech, in partnership with Pfizer, has driven forward the development and commercialization of mRNA vaccines, while Pfizer has leveraged its broader pharmaceutical portfolio to reinforce its market leadership. CureVac is focused on mRNA-based therapies for cancer and infectious disease, and Sanofi, Arcturus Therapeutics, and GreenLight Biosciences are also named as key players advancing mRNA technology through their own research and development programs. Emerging players including eTheRNA, Providence Therapeutics, and Gennao Bio are investing in R&D to capture a share of the growing market.

Market Restraints

Regulatory challenges and stringent approval processes can delay the commercialization of new mRNA therapies, while the high cost of research and development, combined with the complexity of manufacturing, creates a significant barrier to entry for new market participants.

Related Reports

https://www.strategicrevenueinsights.com/industry/coronary-heart-disease-diagnostic-imaging-device-market

https://www.strategicrevenueinsights.com/industry/cro-for-biotech-market

https://www.strategicrevenueinsights.com/industry/dental-inlays-and-onlays-market

https://www.strategicrevenueinsights.com/industry/diagnostic-imaging-services-market

https://www.strategicrevenueinsights.com/industry/digital-therapeutics-mental-health-tech-market

Frequently Asked Questions

What is the mRNA therapeutics market size and growth forecast?

The market was valued at USD 22.0 billion in 2025 and is projected to reach USD 61.0 billion by 2034, growing at a CAGR of 12.00%.

What is driving growth in the mRNA therapeutics market?

Growth is driven by increasing demand for innovative treatments, technological advancements in delivery platforms, and government support for biotechnology research.

Which region leads the mRNA therapeutics market?

North America leads the market due to its advanced healthcare infrastructure and significant R&D investment, while Asia Pacific is the fastest-growing region.

Who are the leading companies in the mRNA therapeutics market?

Moderna, BioNTech, and Pfizer are the leading companies, with CureVac, Sanofi, and Arcturus Therapeutics also recognized as key players.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases